Label-free determination of prostate specific membrane antigen in human whole blood at nanomolar levels by magnetically assisted surface enhanced Raman spectroscopy
Autor: | Zdenka Medříková, Radek Zbořil, Jan Konvalinka, Pavel Šácha, Petr Beneš, Jitka Bařinková, Václav Ranc, Zuzana Chaloupková, Anna Balzerová |
---|---|
Rok vydání: | 2018 |
Předmět: |
Glutamate Carboxypeptidase II
Male Silver Nanotechnology 02 engineering and technology Spectrum Analysis Raman Biochemistry Ferric Compounds Antibodies Analytical Chemistry Nanocomposites 03 medical and health sciences Prostate cancer 0302 clinical medicine Limit of Detection Glutamate carboxypeptidase II medicine Biomarkers Tumor Environmental Chemistry Humans Spectroscopy Early Detection of Cancer Label free Whole blood Detection limit biology Chemistry Prostatic Neoplasms Surface-enhanced Raman spectroscopy 021001 nanoscience & nanotechnology medicine.disease 3. Good health 030220 oncology & carcinogenesis Antigens Surface Cancer research biology.protein Magnets Biomarker (medicine) Antibody 0210 nano-technology |
Zdroj: | Analytica Chimica Acta |
ISSN: | 0003-2670 |
DOI: | 10.1016/j.aca.2017.10.008 |
Popis: | Prostate cancer is one of the most common cancers among men and can in its later stages cause serious medical problems. Due to the limited suitability of current diagnostic biochemical markers, new biomarkers for the detection of prostate cancer are highly sought after. An ideal biomarker should serve as a reliable prognostic marker, be applicable for early diagnosis, and be applicable for monitoring of therapeutic response. One potential candidate is glutamate carboxypeptidase II (GCPII), also known as prostate specific membrane antigen (PSMA), which has a promising role for direct imaging. GCPII is considerably over-expressed on cancerous prostatic epithelial cells; its analysis typically follows radiological or spectrophotometric principles. Its role as a biomarker present in blood has been recently investigated and potential correlation between a concentration of GCPII and prostate cancer has been proposed. The wider inclusion of GCPII detection in clinical praxis limits mainly the time and cost per analysis. Here, we present a novel analytical nanosensor applicable to quantification of GCPII in human whole blood consisted of Fe3O4@Ag magnetic nanocomposite surface-functionalized by an artificial antibody (low-molecular-weight GCPII synthetic inhibitor). The nanocomposite allows a simple magnetic isolation of GCPII using external magnetic force and its consecutive determination by magnetically assisted surface enhanced Raman spectroscopy (MA-SERS) with a limit of detection 6 pmol. L−1. This method enables a rapid determination of picomolar concentrations of GCPII in whole human blood of healthy individuals using a standard addition method without a complicated sample pre-treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |